Showing results (21-30 of 129) with videos related to
Sort By:
Pageof 13
PET Clinics|May 10, 2016
PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and MetabolismVikas Prasad, Valentina Ambrosini, Abass Alavi, et al.PET Clinics|May 10, 2016
PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and MetabolismVikas Prasad, Valentina Ambrosini, Abass Alavi, et al.Journal of Neuroendocrinology|November 22, 2024
The role of combined FDG and SST PET/CT in neuroendocrine tumorsMartina Di Franco, Emilia Fortunati, Lucia Zanoni, et al.European Journal of Radiology|August 31, 2010
PET/CT with 68Gallium-DOTA-peptides in NET: an overviewValentina Ambrosini, Davide Campana, Paola Tomassetti, et al.Clinical Nuclear Medicine|May 17, 2014
68Ga DOTANOC PET/CT detects primary malignant insulinomaValentina Ambrosini, Davide Campana, Cristina Nanni, et al.European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2009
Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CTVikas Prasad, Valentina Ambrosini, Merten Hommann, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 16, 2012
Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?Valentina Ambrosini, Davide Campana, Cristina Nanni, et al.Clinical Nuclear Medicine|February 23, 2013
(18)F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective studyValentina Ambrosini, Maurizio Zompatori, Luca Fasano, et al.Clinical Nuclear Medicine|May 23, 2012
68Ga DOTANOC PET/CT detects medullary thyroid cancer relapse at bone levelSilvia Nicolini, Valentina Ambrosini, Ambrosini Valentina, et al.European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2011
A new dimension of FDG-PET interpretation: assessment of tumor biologyThomas C Kwee, Sandip Basu, Babak Saboury, et al.Pageof 13